Posts on ‘September 7th, 2010’

Agreement provides for an exclusive option for St. Jude Clinical to acquire CardioMEMS in the future and creates opportunity for the Minnesota-based medical device company to expand and accelerate its efforts in heart failure monitoring ST. PAUL, Minn. a…
Devices, Cardiology, Monitoring, Venture Capital
CardioMEMS, St. Jude Pharma

Transaction Valued at More than $300 Million; Includes Anticancer Compounds Carfilzomib and ONX 0912 EMERYVILLE, Calif., Sept. 8 (HSMN NewsFeed) — Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX ) today announced that it has entered into an exclusive agreeme…
Biopharmaceuticals, Oncology
Onyx Pharmaceuticals, Ono Medical, carfilzomib, ONX 0912

Builds on Long-standing Commitment to Virology Gains Full Rights to Promising Phase II Hepatitis C Biologic, Pegylated-Interferon Lambda Obtains FDA-Approved Specialty Surgical Biologic, RECOTHROM® Attains Early Clinical and Pre-clinical Progr…
Biopharmaceuticals, Mergers & Acquisitions
Bristol-Myers Squibb, ZymoGenetics, Pegylated-Interferon, RECOTHROM, thrombin

SALT LAKE CITY, Sept. 7 (HSMN NewsFeed) — Amedica Corporation, a developer of a broad range of innovative, unique spine and total joint implants, announced that it has completed a $30 million financing. The financing consists of $15 million in intimate …
Devices, Orthopaedic
Amedica Corp, silicon nitride

RYE, N.Y., Sept. 7 (HSMN NewsFeed) — Curemark (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that James F. Szigethy, formerly a consultant for Curemark, has assumed the career opportunity o…
Biopharmaceuticals, Neurology, Personnel
Curemark